PPH logo

PPH VanEck Pharmaceutical ETF

$108.10
$0.04
(0.04%)
Today
50

Neutral Sentiment

How do you feel about PPH?

Loading...
NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day — Direct US Listing Talks, Drug Approval Fail To Halt Slip
NVO stock is down 11% this week, on track for its worst week since late February if losses hold.
Stocktwits
NVO Stock Jumps 4% As European Committee Backs Novo’s Haemophilia Pen
The Committee for Medicinal Products for Human Use recommended European Union marketing authorization for Frehemgo in adults and children with haemophilia A on Thursday.
Stocktwits
Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs
Trump's latest MFN drug-pricing deals create a mixed outlook for the broader healthcare sector ETFs.
Zacks
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
Zacks
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
Zacks
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Sector ETF report for PPH
Zacks
NVO Stock Drops 6% Despite Raised Guidance As Investors Worry About Injectable GLP-1 Sales Future
Novo now expects underlying sales and operating profit in the range of 0% to –6% for the year.
Stocktwits
NVO Stock Ends Three-Month Winning Streak As Novo Nordisk’s Key Heart Drug Flops, Competition Goes To Court
The Danish drugmaker reported on Friday that its experimental cardiovascular drug ziltivekimab failed a key late-stage trial, marking a significant pipeline setback in its efforts to diversify beyond blockbuster obesity and diabetes treatments.
Stocktwits
Will Generic Drug Tariffs Impact Pharma ETFs?
New U.S. tariffs on generic drugs could pressure drugmakers and influence pharmaceutical ETFs. Here's what investors should watch.
Zacks